spironolactone has been researched along with warfarin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dölle, W; Goebell, H | 1 |
| Waddell, WR | 1 |
| Chiou, WL; Smith, LD | 1 |
| O'Reilly, RA | 1 |
| Clark, A; Cleland, JG; Coletta, AP; Louis, A; Nikitin, N | 1 |
| CASCIO, G; PALAZZOADRIANO, M | 2 |
| McKelvie, R | 2 |
| Pieper, PG | 1 |
| Hsu, WT; Lee, CM; Shen, LJ | 1 |
| Ding, X; Huo, Q; Liang, L; Pang, M; Su, W; Zhang, H; Zhao, Y | 1 |
5 review(s) available for spironolactone and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplerenone; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Spironolactone; Ventricular Dysfunction, Left; Warfarin | 2003 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Defibrillators, Implantable; Digoxin; Exercise; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Spironolactone; Warfarin | 2004 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Cardiotonic Agents; Defibrillators, Implantable; Digoxin; Exercise; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Spironolactone; Warfarin | 2004 |
Use of medication for cardiovascular disease during pregnancy.
Topics: Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Spironolactone; Warfarin | 2015 |
1 trial(s) available for spironolactone and warfarin
| Article | Year |
|---|---|
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.
Topics: Anticoagulants; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electrocardiography; Eplerenone; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Spironolactone; Ventricular Dysfunction, Left; Warfarin | 2003 |
17 other study(ies) available for spironolactone and warfarin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
[Budd-Chiari syndrome after taking contraceptive drugs].
Topics: Adult; Ascites; Budd-Chiari Syndrome; Contraceptives, Oral; Coumarins; Ethinyl Estradiol; Female; Heparin; Hepatomegaly; Humans; Norgestrel; Spironolactone | 1972 |
Chemotherapy for carcinoma of the pancreas.
Topics: Adult; Aged; Autopsy; Biopsy; Carcinoma; Female; Fluorouracil; Humans; Laparotomy; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Spironolactone; Testolactone; Warfarin | 1973 |
Adsorption of organic compounds by commercial filter papers and its implication on quantitative--qualitative chemical analysis.
Topics: Adsorption; Chemistry Techniques, Analytical; Ethinyl Estradiol; Filtration; Griseofulvin; Naphthalenes; Paper; Solubility; Spironolactone; Warfarin; Water | 1970 |
Spironolactone and warfarin interaction.
Topics: Adult; Diuretics; Drug Interactions; Enzyme Induction; Hematocrit; Humans; Liver; Male; Prothrombin Time; Spironolactone; Warfarin | 1980 |
[PHARMACOLOGICAL ACTIONS OF 2 HETEROCYCLIC GLYOXYLIC ALDEHYDES WITH NOTABLE DIURETIC ACTIVITY].
Topics: Aldehydes; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Chlorothiazide; Coumarins; Diuretics; Electrolytes; Hepatitis; Hepatitis A; Hydrochlorothiazide; Pharmacology; Rats; Research; Spironolactone; Urine | 1964 |
[CHARACTERIZATION OF THE DIURETIC EFFECT OF COUMARIN-3-GLYOXYLIC ALDEHYDE].
Topics: Aldehydes; Aldosterone; Body Fluids; Carbon Tetrachloride; Chlorothiazide; Coumarins; Diuretics; Electrolytes; Pharmacology; Rats; Research; Spironolactone; Urine | 1963 |
Drug-related problems vary with medication category and treatment duration in Taiwanese heart failure outpatients receiving case management.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Case Management; Diuretics; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Heart Failure; Humans; Male; Middle Aged; Outpatients; Prospective Studies; Spironolactone; Taiwan; Warfarin | 2016 |
Isolated right ventricular noncompaction caused ventricular tachycardia and pulmonary embolism.
Topics: Adrenergic beta-Agonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Heart Ventricles; Heparin; Humans; Isolated Noncompaction of the Ventricular Myocardium; Magnetic Resonance Imaging; Male; Pulmonary Embolism; Radiofrequency Ablation; Spironolactone; Tachycardia, Ventricular; Tomography, Emission-Computed, Single-Photon; Warfarin; Young Adult | 2020 |